Medindia LOGIN REGISTER
Medindia

Is Genetic Therapy the Answer to Progressive Muscle Disorder in Mice?

by Colleen Fleiss on Apr 14 2023 11:24 PM
Listen to this article
0:00/0:00

Is Genetic Therapy the Answer to Progressive Muscle Disorder in Mice?
In mice with myotonic dystrophy, administration of a new targeted drug was found to restore muscle strength and correct myotonia. The research, which is published in Nature Communications, could lead to new treatments for affected patients.
People with myotonic dystrophy experience progressive muscle weakness and repeated episodes of painless muscle stiffness called myotonia.

Myotonia in myotonic dystrophy is caused by abnormal processing (or splicing) of the transcript created from the gene that codes for the muscle chloride channel Clcn1, a protein that controls the flow of chloride ions into muscle cells.

Who Can Benefit From Genetic Therapy For Progressive Muscle Disorder

The abnormal splicing leads to a truncated and poorly functioning Clcn1.

Also, the degree of weakness in patients with myotonic dystrophy is associated with higher amounts of oxidative, rather than glycolytic, muscle fibers. These fibers differ in how they obtain energy for contraction.

To correct the abnormal splicing in mice with myotonic dystrophy, a team led by Thurman Wheeler, MD, a neuromuscular researcher at MGH and an associate professor of Neurology at Harvard Medical School, used a genetic therapy involving small pieces of DNA called antisense oligonucleotides (ASOs).

The ASOs were based on a code that targets the abnormal splicing of Clcn1, and when injected directly into the animals’ muscles, the ASOs corrected the abnormality, boosted the abundance of functional Clcn1, increased the amount of glycolytic muscle fibers, and restored muscle health.

Additional co-authors include Ningyan Hu, Eunjoo Kim, and Layal Antoury.

Advertisement
This work was supported by the Elaine and Richard Slye Fund and the Muscular Dystrophy Association.

Source-Eurekalert


Advertisement